Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Large national cohort study with 34,427 consecutive CLL diagnoses, multivariable analysis adjusting for key confounders, and hard clinical endpoints (overall and cause-specific survival) demonstrating previously unreported socioeconomic and geographic disparities.
This is a mechanistic discovery study using novel proteomics methodology to identify a protein interaction and propose a regulatory mechanism; it lacks clinical outcome data, patient treatment results, or even cell-based validation of therapeutic efficacy.
A single case report raising a novel hypothesis about zanubrutinib-associated ocular surface dysfunction; descriptive rather than comparative, with no control group or quantified incidence.
Single-centre retrospective audit of compliance with published ESC surveillance guidance; identifies practice gaps rather than testing an intervention, with no comparator group or efficacy endpoint.
This is a bioinformatic analysis of gene expression data identifying potential compensatory pathways after LEF1 disruption; it raises mechanistic questions rather than testing them functionally or clinically, and requires experimental validation.